BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
What's Your Number one Superhuman Film Made? - 2Instructions to Plan for Your Teeth Substitution Methodology
- 3VPN Administrations for Online Protection
- 4How comfort foods trigger pleasure in our brains
- 5James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball'
- In blow to Lula, Brazil Congress revives controversial environmental bill
- Mossad unveils network of Hamas terror infrastructure across Europe
- Vote In favor of Your Number one Sort Of Blossoms
- The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Courageous Climbing: Trails and Stuff for Outside Lovers
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
